Jazz Pharmaceuticals Plc - 10-Q Summary (Period Ended Sep 30, 2007)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2007, for Jazz Pharmaceuticals, Inc. (Jazz). The company is a specialty pharmaceutical firm focused on neurology and psychiatry. Key products include Xyrem (sodium oxybate) for narcolepsy and Antizol (fomepizole) for poisonings. In June 2007, the company completed its Initial Public Offering (IPO), raising approximately $97.4 million in net proceeds. In March 2007, the company divested its rights to Cystadane.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 |
|---|---|---|
| Total Revenues | $21,474 | $49,826 |
| Net Loss | $(19,359) | $(78,806) |
| Loss per Share (Basic & Diluted) | $(0.82) | $(7.50) |
| Cash and Cash Equivalents | $119,972 | $119,972 (Balance Sheet) |
| Total Assets | $258,767 | $258,767 (Balance Sheet) |
| Senior Secured Notes (Debt) | $74,862 | $74,862 (Balance Sheet) |
| Accumulated Deficit | $(256,449) | $(256,449) (Balance Sheet) |
Liquidity: As of September 30, 2007, the company held approximately $130.9 million in cash, cash equivalents, and marketable securities. Net cash used in operating activities for the nine months ended September 30, 2007, was $53.0 million, while net cash provided by financing activities was $98.1 million, primarily driven by the IPO.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 87% for the three months and 54% for the nine months compared to the prior year periods. This was driven by a 20% increase in product sales (primarily Xyrem) and a significant surge in contract revenue (up 4,706% for the quarter) due to a $7.5 million milestone payment from UCB for JZP-6 clinical trials.
- Net Loss: The company reported a net loss of $19.4 million for the quarter, compared to a net income of $7.7 million in the same period in 2006. The prior year income was significantly boosted by a one-time $31.6 million gain on the extinguishment of a development financing obligation, which did not recur in 2007.
- Government Settlement: In the nine months ended September 30, 2007, the company recorded a $17.5 million charge related to a settlement with the U.S. government regarding the marketing of Xyrem. This resulted in a liability of approximately $20.0 million to be paid over five years.
- Divestiture: The company sold its rights to Cystadane in March 2007 for $9.0 million, recording a gain of $5.1 million. Consequently, Cystadane sales were zero in the current period compared to $369,000 in the prior quarter.
Guidance, Outlook, and Risks
- Luvox CR Launch: The company is preparing to launch Luvox CR (fluvoxamine maleate extended release) in the U.S. for obsessive compulsive disorder and social anxiety disorder. The FDA's PDUFA date for action is December 22, 2007. The company expects to incur significant expenses in late 2007 and 2008 related to this launch, including sales force expansion and milestone payments to Solvay.
- JZP-6 Development: The company is conducting Phase III trials for JZP-6 (sodium oxybate) for fibromyalgia syndrome, with preliminary data expected in the second half of 2008.
- Profitability Outlook: Management expects to continue incurring net losses for the next several years due to high R&D and commercialization costs. The company anticipates needing to raise additional funds to support operations.
- Risks: Key risks include the potential failure of Luvox CR or JZP-6 to receive FDA approval, the expiration of orphan drug exclusivity for Antizol in December 2007, and the financial impact of the $20 million government settlement. Additionally, the company relies on single-source suppliers for its active pharmaceutical ingredients.
Investor Verification Checklist
- Luvox CR Approval Status: Verify the FDA's decision on the Luvox CR NDA by the December 22, 2007 PDUFA date, as this is critical for near-term revenue growth.
- Government Settlement Payments: Monitor the company's ability to meet the scheduled payments totaling $20 million over the next five years and ensure no acceleration clauses are triggered.
- Antizol Generic Competition: Assess the impact of the December 2007 expiration of orphan drug exclusivity for Antizol on revenue and margins.
- Cash Burn Rate: Review the company's cash position relative to its operating burn rate to determine the timeline for potential future capital raises.
- Supply Chain: Confirm the status of FDA qualification for new suppliers (e.g., Patheon for Xyrem, Lonza for Luvox CR API) to ensure no manufacturing disruptions.